Alphamab Oncology (HK:9966) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology has announced successful passage of all proposed resolutions at its Annual General Meeting held on June 12, 2024, with overwhelming shareholder approval. Key resolutions included the re-election of board members, authorization for the company to repurchase and issue shares, and the reappointment of Deloitte Touche Tohmatsu as auditors. These strategic approvals signal strong shareholder confidence and pave the way for the company’s future initiatives.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.